Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-12-20
2009-11-24
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S388150, C530S387700, C424S130100, C424S133100, C424S138100, C424S139100, C424S141100, C424S143100, C435S810000
Reexamination Certificate
active
07622560
ABSTRACT:
The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5641860 (1997-06-01), Park et al.
patent: 5879911 (1999-03-01), Park et al.
patent: 5942404 (1999-08-01), Park et al.
patent: 6225286 (2001-05-01), Park et al.
patent: 1 033 410 (2000-09-01), None
patent: WO 2004/026120 (2004-04-01), None
The Merck Manuals Online Medical Library, [online]. Whitehouse Station, NJ: Merck Research Laboratories, 2006-2007. [retrieved on Oct. 9, 2007]. Retrieved from the Internet: < URL:http://www.merck.com/mmpe/print/sec11/ch142/ch142b.html >. Acute Leukemia, see pp. 1-5.
Dillamn, Journal of Clinical Oncology, 1994, 12:1497-1515.
Pallant et al., Proc Nall Acad Sci USA. 1989, 86:1328-32.
Shelley et al., Proc Natl Acad Sci USA 1989, 86:2819-23.
Carlsson et al., JBiol Chem. 1986, 261:12787-95.
Shelley et al., Biochem J. 1990, 270:569-76.
Remold-O'Donnell et al., Blood. 1987, 70:104-9.
Fukuda, Glycobiology. 1991, 1:347-56.
Fernandez-Rodriguez et al., Tumour Biol. 2002, 23:193-201.
Sikut et al, Int J Cancer. 1999, 82:52-8.
Jung et al, Korean J Pathol. 38:8-14.
Rosenstein et al., Immunol Res. 1999, 20:89-99.
Piller et al., JBiol Chem. 1988, 263:15146-50.
Fox et al., J Immunol. 1983, 131:762-7.
Saitoh et al., Blood. 1991, 77:1491-9.
Borche et al., Eur JImmunol. 1987,17:1523-6.
Stefanova et al., Folia Biol (Praha). 1988, 34:255-65.
Alvarado et al., Eur J Immunol. 1995, 25:1051-5.
Stross et al, J Clin Pathol. 1989, 42:953-61.
Horejsi et al., 1997, In Kishimoto T, et al, Leucocyte Typing, vol. VI: White Cell Differentiation Antigens 494. Garland, New York and London.
Tkaczuk et al., Tissue Antigens. 1999, 54:1-15.
Sikut et al., Int J Cancer. 1999, 82:52-8.
Mukasa et al, Int lmmunol. 1999, 11:259-68.
Shaw, et al., J. Immunol., 138:4534 (1987).
Sun, LK., et al., Proc. Natl. Acad. Sci. USA, 84:214-218 (1987).
Queen et al. (1989) Proc. Nat'l Acad. Sci. USA 86:10029-10033.
Antibody Engineering: A Practical Approach (Oxford University Press 1996).
Koeler & Milstein Nature, 1975, 256, 495-497.
Haraguchi et al., Proc. Natl. Acad. Sci. U S. A. 1994,91: 10455-9.
Davis et al., Methods in Molecular Biology, Elsevier Science, New York 1986:285-289.
Wysocki et al., Proc. Natl. Acad. Sci. U. S. A. 1978, 75:2844-8.
Polito et al., 2004.
Written Opinion of the International Searching Authority of Corresponding PCT Application:PCT/KR2006/000870; Date: Jun. 2, 2006.
PCT International Search Report; PCT/KR/2006/000870; Date: Jun. 2, 2006.
UNIpROT Database Entry, Accession No. P16150. Apr. 1, 1990. [Retrieved online May 17, 2006]. EBI Uniprot Database.
Park WS, Chae JS, Jung KC, Choi WJ, Kook MC, Bae Y. Productin and atahe characterization of monoclonal antibody against CD43, K06. Tissue Antigens. Jan. 2004;63(1); 46-53.
Chung, June-Key, et al., “In Vitro and in Vivo Properties of Murine Monoclonal Antibody for a Novel Immature Thymocyte-Differentiated Antigen, JL1,”Nuclear Medicine & Biology, 1997, vol. 24, pp. 433-437.
Chung, Junho, et al., “Identification of antigenic peptide recognized by the anti-JL1 leukemia-specific monoclonal antibody from combinatorial peptide phage display libraries,”J. Cancer Res Clin Oncolo, 2002, 128: 641-649.
Kim, Tae Kin, et al., “Immunotherapeutic Potential of JL1, a Thymocyte Surface Protein, for Leukemia,”J. Korean Med Sci, 1998, 13: 455-458.
Lee, Geon Kook, et al., “LFA-1- and ICAM-1-dependent Homotypic Aggregation of Human Thymocytes Induced by JL1 Engagement,”Mols. Cells, 1999, vol. 9, No. 6, pp. 662-667.
Park, Seong Hoe, et al., “JL1, A Novel Differentiation Antigen of Human Cortical Thymocyte,”J. Exp. Med., Oct. 1993, vol. 178, pp. 1447-1451.
Park, W.S., et al., “Production and the characterization of monoclonal antibody against CD43, K06,”Tissue Antigens, 2004, 63: 46-53.
Park, W.S., et al., “A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias,”Leukemia, 1998, vol. 12, pp. 1583-1590.
Shin, Young Kee, et al., “Expression of Leukemia-Associated Antigen, JL1, in Bone Marrow and Thymus,”American Journal of Pathology, Apr. 2001, vol. 158, No. 4, pp. 1473-1480.
Shin, Young Kee, et al., “Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications,”Cancer Immunol Immunother, 2003, 52: 506-512.
Shin, Young Kee, et al., “Immature thymocyte antigen, JL1, as a possible immunodiagnostic and immunotherapeutic target for leukemia,”Immune Network, 2001, vol. 1, No. 1, pp. 1-6.
Suh, Wonhee, et al., “Anti-JL1 antibody-conjugated poly (L-lysine) for targeted gene delivery to leukemia T cells,”Journal of Controlled Release, 2001, vol. 72, pp. 171-178.
Saati, T. A., et al., “A Novel Antigen Detected by the CBF.78 Antibody Further Distinguishes Anaplastic Large Cell Lymphoma from Hodgkin's Disease,”Blood, Oct. 11, 1995, vol. 86, No. 7, pp. 2741-2748.
Supplemental European Search Report for PCT/KR2006/000870 dated Sep. 4, 2008.
Choi Eun-Young
Jung Kyeong-Cheon
Park Seong-Hoe
Park Seong-Pyo
Dinona Inc.
Gambel Phillip
Townsend and Townsend / and Crew LLP
Wen Sharon
LandOfFree
Monoclonal antibody specific for CD43 epitope does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody specific for CD43 epitope, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody specific for CD43 epitope will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4056884